James Sapirstein, President and CEO, AzurRx BioPharma, a clinical stage biopharmaceutical company specializing in therapies for gastrointestinal diseases talks about turning their focus to the virus that causes COVID-19. With a background in drug development for HIV and infectious diseases, James describes their approach to developing an oral agent targeted to COVID-19 long-haulers. AzurRx is working on an indication for COVID-19 of gastrointestinal issues that is showing that the Sars-CoV-2 virus stores itself in the reservoirs inside the human body including the gastrointestinal tract. @azurrx #AzurRxBioPharma #COVID19 #GIDrugs #GIDiseases #COVIDLongHaulers $AZRX AzurRx.com Download the transcript here